Clinical Trial Update: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bemarituzumab plus chemotherapy versus placebo plus chemotherapy in FGFR2b-overexpressing gastric and gastroesophageal junction cancers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Bemarituzumab (bemarituzumab)

Snippet

Sponsor: Amgen | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING